TGFB1 and metastatic neoplasm: TGF-β inhibitors can increase the sensitivity of anti PD-1/PD-L1 therapy in the mouse models of progressive liver metastatic diseases, which may be due to TGF-β inhibition resulting in an effective and long-lasting cytotoxic T-cell response to tumor cells 114.